ReviewCurrent pharmaceutical design2024
Prescription Precision: A Comprehensive Review of Intelligent Prescription Systems.
Review in Current pharmaceutical design, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Contexts and Mechanisms Related to the Efficacy of Digital Medication Adherence Interventions to Support Medication Adherence Among Adults With Chronic Diseases: Realist Review.Interactive journal of medical research · 2026Review
- Intelligent Medication Recommendation via Dynamic Prescription Modeling and Molecular Substructure Learning.Interdisciplinary sciences, computational life sciences · 2026Article
- Descriptive analysis of prescription interception patterns: characterizing medication safety risks in an outpatient setting.Frontiers in pharmacology · 2026Article
- The Role of Artificial Intelligence in Reducing Dispensing Errors for Patient Safety and Quality: A Systems Approach.Risk management and healthcare policy · 2026Article
- Community pharmacists' perspectives on E-pharmacy: an imminent threat or an opportunity in disguise?Frontiers in medicine · 2026Article
- Medicine use during breastfeeding in Uganda: stakeholder perspectives on barriers and facilitators.International breastfeeding journal · 2025Article
- Article
- Optimization and impact of an evidence-based pre-audit prescription decision system in primary healthcare settings.Frontiers in pharmacology · 2025Article
- A critical look into artificial intelligence and healthcare disparities.Frontiers in artificial intelligence · 2025Article
- Artificial intelligence, medications, pharmacogenomics, and ethics.Pharmacogenomics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intelligent Prescription Systems (IPS) represent a promising frontier in healthcare, offering the potential to optimize medication selection, dosing, and monitoring tailored to individual patient needs. This comprehensive review explores the current landscape of IPS, encompassing various technological approaches, applications, benefits, and challenges. IPS leverages advanced computational algorithms, machine learning techniques, and big data analytics to analyze patient-specific factors, such as medical history, genetic makeup, biomarkers, and lifestyle variables. By integrating this information with evidence-based guidelines, clinical decision support systems, and real-time patient data, IPS generates personalized treatment recommendations that enhance therapeutic outcomes while minimizing adverse effects and drug interactions. Key components of IPS include predictive modeling, drug-drug interaction detection, adverse event prediction, dose optimization, and medication adherence monitoring. These systems offer clinicians invaluable decision-support tools to navigate the complexities of medication management, particularly in the context of polypharmacy and chronic disease management. While IPS holds immense promise for improving patient care and reducing healthcare costs, several challenges must be addressed. These include data privacy and security concerns, interoperability issues, integration with existing electronic health record systems, and clinician adoption barriers. Additionally, the regulatory landscape surrounding IPS requires clarification to ensure compliance with evolving healthcare regulations. Despite these challenges, the rapid advancements in artificial intelligence, data analytics, and digital health technologies are driving the continued evolution and adoption of IPS. As precision medicine gains momentum, IPS is poised to play a central role in revolutionizing medication management, ultimately leading to more effective, personalized, and patient-centric healthcare delivery.
Indexed as
Identifiers
39092640What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.